Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Tornier N.V. (TRNX): Are Hedge Funds Right About This Stock?

Page 1 of 2

Is Tornier N.V. (NASDAQ:TRNX) a buy right now? The smart money is becoming more confident. The number of bullish hedge fund bets increased by 7 in recent months.

In today’s marketplace, there are dozens of indicators investors can use to track the equity markets. A couple of the most under-the-radar are hedge fund and insider trading activity. At Insider Monkey, our studies have shown that, historically, those who follow the best picks of the top fund managers can outperform their index-focused peers by a very impressive amount (see just how much).

SAC CAPITAL ADVISORSEqually as beneficial, optimistic insider trading sentiment is a second way to break down the financial markets. Obviously, there are lots of stimuli for a bullish insider to downsize shares of his or her company, but only one, very clear reason why they would buy. Various empirical studies have demonstrated the useful potential of this tactic if you know where to look (learn more here).

Now, let’s take a peek at the key action encompassing Tornier N.V. (NASDAQ:TRNX).

Hedge fund activity in Tornier N.V. (NASDAQ:TRNX)

At the end of the first quarter, a total of 14 of the hedge funds we track held long positions in this stock, a change of 100% from the first quarter. With the smart money’s sentiment swirling, there exists a few notable hedge fund managers who were upping their stakes considerably.

Of the funds we track, Steven Cohen’s SAC Capital Advisors had the most valuable position in Tornier N.V. (NASDAQ:TRNX), worth close to $13.2 million, accounting for 0.1% of its total 13F portfolio. On SAC Capital Advisors’s heels is SAC Subsidiary of CR Intrinsic Investors, with a $12.4 million position; 0.4% of its 13F portfolio is allocated to the stock. Other peers with similar optimism include Paul Tudor Jones’s Tudor Investment Corp, Israel Englander’s Millennium Management and SAC Subsidiary’s Sigma Capital Management.

As one would reasonably expect, some big names have jumped into Tornier N.V. (NASDAQ:TRNX) headfirst. Tudor Investment Corp, managed by Paul Tudor Jones, assembled the most valuable position in Tornier N.V. (NASDAQ:TRNX). Tudor Investment Corp had 7.5 million invested in the company at the end of the quarter. SAC Subsidiary’s Sigma Capital Management also initiated a $2.2 million position during the quarter. The following funds were also among the new TRNX investors: Israel Englander’s Catapult Capital Management, Donald Chiboucis’s Columbus Circle Investors, and John Overdeck and David Siegel’s Two Sigma Advisors.

How are insiders trading Tornier N.V. (NASDAQ:TRNX)?

Insider trading activity, especially when it’s bullish, is particularly usable when the company in focus has seen transactions within the past half-year. Over the last six-month time frame, Tornier N.V. (NASDAQ:TRNX) has seen zero unique insiders purchasing, and 5 insider sales (see the details of insider trades here).

Let’s check out hedge fund and insider activity in other stocks similar to Tornier N.V. (NASDAQ:TRNX). These stocks are Endologix, Inc. (NASDAQ:ELGX), Luminex Corporation (NASDAQ:LMNX), ICU Medical, Incorporated (NASDAQ:ICUI), Cantel Medical Corp. (NYSE:CMN), and Conceptus, Inc. (NASDAQ:CPTS). This group of stocks belong to the medical instruments & supplies industry and their market caps resemble TRNX’s market cap.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!